Sugi Predict

Sugi Predict / Compounds / SCHEMBL1244982

SCHEMBL1244982

SCHEMBL1244982

CCc1csc(C(=O)O)n1

nearest known ligand 0.41

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ PLA2G4A P47712 1/20 0.41
▸ DAO P14920 1/20 0.40
▸ KMT2A Q03164 5/20 0.39
▸ MEN1 O00255 4/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ GABRA5 P31644 1/20 0.39
▸ GABRB2 P47870 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ NPC1 O15118 2/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ HCAR2 Q8TDS4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9051929 0.86 KMT2A (0.40) PLA2G4ADAOKMT2AMEN1ALDH1A1
SCHEMBL2877357 0.85 PLA2G4A (0.43) PLA2G4ADAOKMT2AMEN1ALDH1A1
SCHEMBL16603280 0.84 ALDH1A1 (0.39) PLA2G4ADAOKMT2AMEN1ALDH1A1
SCHEMBL17717276 0.82 KMT2A (0.44) PLA2G4AKMT2AMEN1ALDH1A1GABRA5
SCHEMBL27647396 0.82 PLA2G4A (0.48) PLA2G4AKMT2AMEN1ALDH1A1GABRA5
SCHEMBL1421329 0.82 GABRA5 (0.40) PLA2G4AKMT2AMEN1ALDH1A1GABRA5
SCHEMBL17006970 0.80 GABRA5 (0.39) PLA2G4AKMT2AMEN1ALDH1A1GABRA5
SCHEMBL128514 0.80 GABRA5 (0.39) PLA2G4AKMT2AMEN1ALDH1A1GABRA5
SCHEMBL4890454 0.80 SMN1; SMN2 (0.50) PLA2G4AKMT2AALDH1A1GABRA5GABRB2
SCHEMBL25134810 0.79 KMT2A (0.40) PLA2G4AKMT2AMEN1ALDH1A1GABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3710428-B1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2026-03-25 — — EP disclosed
CN-119192103-A Five-membered heterocyclic amide compound, preparation method and application thereof, and bactericide 贵州大学 2024-12-27 — — CN disclosed
US-20240307382-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ABBVIE INC. 2024-09-19 — — US disclosed
CN-112204009-B Modulators of integrated stress pathways 卡里科生命科学有限责任公司 2024-05-07 — — CN disclosed
US-11046680-B1 Heteroaryl-substituted triazoles as APJ receptor agonists AMGEN INC. (US) 2021-06-29 — — US disclosed
US-11046680-B1 Heteroaryl-substituted triazoles as APJ receptor agonists AMGEN INC. (US) 2021-06-29 — — US disclosed
CN-112204009-A Modulators of integrated stress pathways 卡里科生命科学有限责任公司 2021-01-08 — — CN disclosed
US-20200345727-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ABBVIE INC. 2020-11-05 — — US disclosed
EP-3541805-B1 HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS AMGEN INC (US) 2020-10-14 — — EP disclosed
EP-3541805-B1 HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS AMGEN INC (US) 2020-10-14 — — EP disclosed
WO-2018097945-A1 HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS AMGEN INC. (US) 2018-05-31 — — WO disclosed
WO-2018097945-A1 HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS AMGEN INC. (US) 2018-05-31 — — WO disclosed
US-20180086752-A1 COMPOSITIONS AND METHODS OF TARGETING MUTANT K-RAS NANTBIO, INC. 2018-03-29 — — US disclosed
US-8476265-B2 Compounds-801 ASTRAZENECA AB (SE) 2013-07-02 — — US disclosed
US-8455483-B2 Compounds—801 ASTRAZENECA AB (SE) 2013-06-04 — — US disclosed
US-20130018037-A1 Compounds - 801 ASTRAZENECA UK LIMITED (GB) 2013-01-17 — — US disclosed
EP-2459572-A2 SPIROCYCLIC AMIDE DERIVATIVES AstraZeneca AB (SE) 2012-06-06 — — EP disclosed
US-20110053909-A1 Compounds - 801 PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) 2011-03-03 — — US disclosed
WO-2011012896-A2 COMPOUNDS - 801 ASTRAZENECA AB (SE) 2011-02-03 — — WO disclosed
WO-2010067102-A1 DIAZASPIRO [5.5] UNDECANE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC-RECEPTOR ANTAGONISTS AND BETA-ADRENORECEPTOR AGONISTS FOR THE TREATMENT OF PULMONARY DISORDERS ASTRAZENECA AB (SE) 2010-06-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11046680-B1 Heteroaryl-substituted triazoles as APJ receptor agonists AGTR1, AGTR2, TBXA2R PLA2G4A 2699/4885DAO 1719/4885KMT2A 3480/4885
US-20130018037-A1 Compounds - 801 ADRA2C, ADRB2, ADRB1 PLA2G4A 4336/4885DAO 1805/4885KMT2A 2392/4885
US-20240307382-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 PLA2G4A 2326/4885DAO 4301/4885KMT2A 4320/4885
US-20180086752-A1 COMPOSITIONS AND METHODS OF TARGETING MUTANT K-RAS KRAS, NRAS, HRAS PLA2G4A 795/4885DAO 3846/4885KMT2A 2128/4885
US-20110053909-A1 Compounds - 801 ADRA2C, ADRB2, ADRB1 PLA2G4A 4336/4885DAO 1805/4885KMT2A 2392/4885
US-20200345727-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 PLA2G4A 2326/4885DAO 4301/4885KMT2A 4320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.